Thread
Compounded copies, patent expiry, grey-market vials and the safety reviews that follow popular drugs.
The open questionWhat can people legally get, and how do regulators react when demand outruns supply?
This thread tracks what happens when demand for a peptide outruns the approved supply: shortage listings, compounded copies, recalls, patent expiry abroad and the unregulated vials sold online. It also records how regulators answered each step. The spine below lists every story in filing order, so the sequence of rule changes and the reasons given for them can be read in one place.
UrgentSAFStart
FDA removed semaglutide from its shortage list and set end dates for compounding: about 60 days for state-licensed pharmacies, about 90 for outsourcing facilities.
60 / 90 days of grace for pharmacy compounders and outsourcing facilities to stop making copies
RoutineEXP+2 mo
A status check on one of the most searched unapproved peptides: what regulators and sport authorities have actually said.
0 approved human medicines containing BPC-157 in the US or EU
UrgentSAF+2 mo
PRAC recommended updating product information for Ozempic, Rybelsus and Wegovy to list NAION as a very rare side effect.
1 in 10,000 estimated upper frequency of NAION, classed as a very rare side effect
RoutineIND+9 mo
Drugmakers announced semaglutide launches after core patent protection ended in India, with other markets including Canada and Brazil on similar timelines.
2026 year core semaglutide patent protection ended in several large markets